MindWalk (NASDAQ:HYFT – Get Free Report) and Fortrea (NASDAQ:FTRE – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.
Valuation and Earnings
This table compares MindWalk and Fortrea”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MindWalk | $11.24 million | 5.82 | -$10.11 million | ($0.26) | -5.38 |
| Fortrea | $2.72 billion | 0.79 | -$986.20 million | ($0.91) | -25.00 |
MindWalk has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for MindWalk and Fortrea, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
| Fortrea | 2 | 3 | 7 | 0 | 2.42 |
MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 257.14%. Fortrea has a consensus price target of $22.60, indicating a potential downside of 0.66%. Given MindWalk’s stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Fortrea.
Volatility and Risk
MindWalk has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.
Profitability
This table compares MindWalk and Fortrea’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MindWalk | -105.11% | -133.26% | -77.78% |
| Fortrea | -3.18% | 10.72% | 2.17% |
Institutional & Insider Ownership
6.7% of MindWalk shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 0.7% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
MindWalk beats Fortrea on 8 of the 14 factors compared between the two stocks.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
About Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Receive News & Ratings for MindWalk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MindWalk and related companies with MarketBeat.com's FREE daily email newsletter.
